Pegylated Liposomal Doxorubicin Hydrochloride

Phase 3

Pegylated Liposomal Doxorubicin Hydrochloride is one of 17 therapeutic programs targeting Metastatic Dedifferentiated Liposarcoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Dedifferentiated LiposarcomaRecruiting

Fallopian Tube High Grade Serous AdenocarcinomaActive, not recruiting

Fallopian Tube Mucinous AdenocarcinomaActive, not recruiting

Fallopian Tube Clear Cell AdenocarcinomaActive, not recruiting

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaNot yet recruiting

Metastatic Dedifferentiated LiposarcomaPhase 1

Recruiting

Fallopian Tube High Grade Serous AdenocarcinomaPreclinical

Active, not recruiting

Fallopian Tube Mucinous AdenocarcinomaPhase 2

Active, not recruiting

Fallopian Tube Clear Cell AdenocarcinomaPhase 3

Active, not recruiting

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Fallopian Tube Clear Cell Adenocarcinoma

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Phase 3

2 2

Taxol

Teva

Phase 3

2 3

Gemzar

Johnson & Johnson

Phase 3

1 4

Recentin

NNational Cancer Institute (NCI)

Phase 3

2 5

Gemzar

GGynecologic Oncology Group

Phase 3

1 6

Paraplatin

AAvyxa

Phase 3

1 7

Pegylated Liposomal Doxorubicin Hydrochloride

NNational Cancer Institute (NCI)

Phase 3

2 8

Hycamtin

MMeitheal

Preclinical

1 9

Hycamtin

GGynecologic Oncology Group

Preclinical

1 10

Cediranib

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Metastatic Dedifferentiated Liposarcoma

NCT05711615

Q1 2027

Phase 3Active, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02446600

PreclinicalActive, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02502266

Q2 2027

PreclinicalActive, not recruiting

Fallopian Tube High Grade Serous Adenocarcinoma

NCT02839707

Phase 2Active, not recruiting

Fallopian Tube Mucinous Adenocarcinoma

NCT04739800

Q2 2029

Phase 2Not yet recruiting

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07504588

Clinical

Trials by Indication[1]

Fallopian Tube Clear Cell Adenocarcinoma2 trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02446600·579 enrolled

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02502266·582 enrolled

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma1 trial

A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07504588·87 enrolled

Metastatic Dedifferentiated Liposarcoma1 trial

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05711615·30 enrolled

Fallopian Tube Mucinous Adenocarcinoma1 trial

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04739800·120 enrolled

Fallopian Tube High Grade Serous Adenocarcinoma1 trial

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02839707·444 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Pegylated Liposomal Doxorubicin Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pegylated Liposomal Doxorubicin Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

Pegylated Liposomal Doxorubicin Hydrochloride

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q2 2029

Trials by Indication[1]

Fallopian Tube Clear Cell Adenocarcinoma2 trials

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma1 trial

Metastatic Dedifferentiated Liposarcoma1 trial

Fallopian Tube Mucinous Adenocarcinoma1 trial

Fallopian Tube High Grade Serous Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News